Biotech Stocks
3 Biotech Stocks That Can Double Before The End Of 2016
And, that is no exaggeration, these three biotech stocks all have near-term catalysts right around the corner that will send their currently undervalued share prices soaring when positive. Grab shares today because the catalysts we’re targeting for growth start happening in September. One of the keys to investing in the small cap portion of the […]
4 Undervalued Growth Stocks Deserving Your Interest
Pick up your pen and paper and write down the names of these four stocks that right now trade for valuations too low for their potential growth. With most stocks tading for premiums right now, finding four growth stocks with attractive valuations to add to your portfolio is worth your attention. I have followed and […]
A Plan Coming Together
An A-Team Biotech Stock Fans of the 80’s TV show “The A-Team” will remember George Peppard’s character, Hanibal, as the leader of the rebellious group of military misfits. At least once a show, he would stick a cigar in his mouth and say, “I love it when a plan comes together.” His face would light […]
4 Likely Biotech Takeover Targets To Buy
After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Bret Jensen shares four more likely takeover targets that should be on your watchlist. It was a good week for the Biotech Gems portfolio. Progenics Pharmaceuticals (NASDAQ: PGNX) leapt 25% in […]
3 Undervalued Stocks With Strong Upcoming Catalysts
If all goes well for these three stocks, in the next six months they could be worth over double the prices they currently trade for. Each stock has important, business-defining events that, if positive (and it’s likely they will be), would make their businesses significantly more valuable. I get dozens of questions every week on […]
Buy These 5 Undervalued Biotech Stocks On Sale Today
One, two, or three years out, investors will probably look back on the entry points in these five stocks and wonder why they did not allocate more funds to them. With growing earnings and revenues and M&A heating up, these five stocks are screaming buys right now. I was out at the Money Show in […]
The One Hit Wonder
How connected are you? If you take away Facebook friends and second & third degree Twitter connections, how many influential people do you know? I have met a couple of famous athletes and entertainers. I have even had meetings with mutual fund managers (the dullest people on earth). I know a few movers and shakers […]
Badges Of Honor For Biotech Penny Stocks
I started as a financial advisor in October 1999. It was a pretty easy sales job. Every morning my computer screen turned green at the opening bell and every stock was broker-proof. Any stock pick made to clients or prospects eventually turned higher. The gains were so quick that a broker could legally churn an […]
Buy These 3 Takeover Targets For 2016
In my last column, I spoke on how M&A chatter has been increasing in the small and mid-cap names within the biotech sector. The derailment of the huge $150 billion merger between Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) is leading many analysts to put forth a list of names these companies could target as they […]
Biotech Is Back: Why The 15% Rally Is For Real
After falling over 40% in six months, the biotech sector has soared 15% in just the last two weeks. The sector remains oversold, creating very appealing entry points. These four companies are Bret Jensen’s favorites to continue the rally. After spending over six months deep in the doldrums, and in the deepest and longest bear […]
The Less You Know The Better
Over the weekend, I heard a quote by legendary Silicon Investor Peter Thiel. He was asked where investors should invest now. It was a timely question because precious metals have been on a tear, unicorns in like Uber are sprouting up like mushrooms after a heavy rain, and Silicon Valley real estate is shooting up […]
